A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis

Table 8 HAE-related HRU, overall and by country

Patients with any HRU episodes, N (%) Annual rate, mean ± SD [median]	Overall (N = 225)	US (n = 56)	Canada (n = 51)	Germany (n = 45)	Australia (n = 35)	UK (n = 24)	Italy (n = 14)
HRU visits (any reason)	137 (60.9) 4.4 ± 9.0 [2.2]	23 (41.1) 3.5 ± 4.4 [2.1]	50 (98.0) 4.3 ± 12.0 [2.2]	N/A	34 (97.1) 5.9 ± 9.1 [2.5]	24 (100) 4.0 ± 4.5 [2.6]	6 (42.9) 1.8 ± 1.8 [1.1]
Routine HAE-related outpatient visits	128 (93.4) 2.3 ± 4.2 [1.6]	21 (91.3) 1.7 ± 2.2 [1.0]	45 (90.0) 1.8 ± 1.1 [1.5]	N/A	33 (97.1) 3.4 ± 7.4 [1.6]	24 (100) 2.6 ± 2.8 [1.9]	5 (83.3) 1.5 ± 1.9 [0.7]
HAE attack-related visits	70 (51.1) 2.8 ± 10.2 [0.7]	12 (52.2) 0.8 ± 1.1 [0.4]	30 (60.0) 3.9 ± 15.2 [0.8]	N/A	19 (55.9) 2.3 ± 3.8 [1.0]	8 (33.3) 2.7 ± 3.4 [0.7]	1 (16.7) 2.9 ± [2.9]
Emergency room visits	53 (38.7) 1.3 ± 1.8 [0.7]	8 (34.8) 0.6 ± 0.7 [0.2]	23 (46.0) 1.0 ± 1.2 [0.8]	N/A	17 (50.0) 1.9 ± 2.4 [0.7]	5 (20.8) 2.1 ± 2.7 [0.7]	0 NA
Hospitalizations	12 (8.8) 1.1 ± 2.3 [0.3]	0 NA	5 (10.0) 0.2 ± 0.1 [0.1]	N/A	4 (11.8) 2.4 ± 3.8 [0.6]	3 (12.5) 1.0 ± 1.2 [0.4]	0 NA
Outpatient visits^a	32 (23.4) 3.5 ± 14.8 [0.3]	7 (30.4) 0.7 ± 1.3 [0.2]	15 (30.0) 6.3 ± 21.6 [0.3]	N/A	4 (11.8) 0.4 ± 0.4 [0.4]	5 (20.8) 1.7 ± 2.3 [0.7]	1 (16.7) 2.9 ± [2.9]

HAE hereditary angioedema, HRU healthcare resource utilization, NA not applicable, N/A not available
^aOutpatient visits included physician visits and other outpatient visits

ISSN: 1710-1492